{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:07:43Z","timestamp":1788768463906,"version":"build-2803163510"},"reference-count":96,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2023.01232.BD"],"award-info":[{"award-number":["2023.01232.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030866","name":"Transcan","doi-asserted-by":"publisher","award":["UCIPredict\u201010.54499\/TRANSCAN3\/0001\/2021"],"award-info":[{"award-number":["UCIPredict\u201010.54499\/TRANSCAN3\/0001\/2021"]}],"id":[{"id":"10.13039\/100030866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Molecular Oncology"],"abstract":"<jats:p>High\u2010risk non\u2010muscle invasive bladder cancer (NMIBC) is a common urological malignancy with a high propensity for recurrence (30\u201340% of patients) despite treatment with Bacillus Calmette\u2013Gu\u00e9rin (BCG) instillations. Identifying patients who are likely to respond or not to BCG therapy before treatment initiation may significantly improve patient outcomes and minimise unnecessary treatments. This systematic review critically assessed the existing literature on the potential of non\u2010invasive biomarkers to predict BCG failure in NMIBC patients. A comprehensive bibliographic search on PubMed, Scopus and Medline databases was conducted to identify relevant studies published up to July 7, 2025. After a thorough screening and selection process, 72 studies were included in the final analysis, 58 of which focused on prognostic markers, 6 on predictive markers, and 8 examined both. Moreover, 55 studies focused on tissue, while 28 studied liquid biopsy\u2010derived biomarkers, showcasing their ability to reflect the dynamic characteristics of the tumour and its microenvironment. The most frequently studied biomarkers comprised p53, Ki\u201067 and pRB. Furthermore, several immunological markers were also explored, highlighting the current challenge of BCG therapy prediction biomarkers. Despite its valuable insights, this systematic review faced limitations within the included studies, such as issues related to reproducibility, feasibility, and small sample sizes. Nonetheless, the findings indicate that a wide array of molecules show potential as prognostic and\/or predictive markers for BCG failure, which may improve the clinical management of this complex disease.<\/jats:p>","DOI":"10.1002\/1878-0261.70329","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:11:26Z","timestamp":1788765086000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive and prognostic biomarkers of Bacillus Calmette\u2010Gu\u00e9rin therapy failure in bladder cancer patients: A systematic review"],"prefix":"10.1002","author":[{"given":"Rui","family":"Ribeiro\u2010Pereira","sequence":"first","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"},{"name":"Master Programme in Oncology, ICBAS\u2010School of Medicine and Biomedical Sciences University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Teixeira\u2010Marques","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"},{"name":"Doctoral Programme in Biomedical Sciences, ICBAS\u2010School of Medicine and Biomedical Sciences University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Freitas","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"},{"name":"Department of Urology Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o A","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"},{"name":"Department of Urology Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Monteiro\u2010Reis","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio I.","family":"Russo","sequence":"additional","affiliation":[{"name":"Urology Section, Department of Surgery University of Catania  Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"},{"name":"Department of Pathology Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2010School of Medicine and Biomedical Sciences University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[{"name":"Cancer Biology and Epigenetics Group IPO Porto Research Center, Portuguese Oncology Institute of Porto (IPO Porto)  Porto Portugal"},{"name":"RISE \u2013 Associate Laboratory (Health Research Network)  Porto Portugal"},{"name":"Porto.CCC \u2013 Porto Comprehensive Cancer Centre Raquel Seruca  Porto Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2010School of Medicine and Biomedical Sciences University of Porto  Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"3","key":"e_1_2_10_2_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01749","article-title":"Editorial: bladder cancer \u2013 a Cinderella Cancer: advances and remaining research questions","volume":"10","author":"Van Hemelrijck M","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters A","year":"2020","journal-title":"World J Urol"},{"issue":"16","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165670","article-title":"Evolution of urothelial bladder cancer in the context of molecular classifications","volume":"21","author":"Minoli M","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open\u2010label, two\u2010stage, multi\u2010arm, phase 1\/2 trial","volume":"17","author":"Sharma P","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2010muscle\u2010invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification Systems for Grade: An update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester RJ","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000000593","article-title":"Use and validation of the AUA\/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort","volume":"203","author":"Ritch CR","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow\u2010up","volume":"33","author":"Powles T","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette\u2010Guerin versus mitomycin C for superficial bladder cancer: a formal meta\u2010analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle A","year":"2003","journal-title":"J Urol"},{"issue":"2","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus Calmette\u2010Gu\u00e9rin\u2010unresponsive non\u2010muscle\u2010invasive bladder cancer: its definition and future therapeutic strategies","volume":"27","author":"Kikuchi E","year":"2020","journal-title":"Int J Urol"},{"issue":"6","key":"e_1_2_10_12_1","first-page":"S199","article-title":"The management of BCG failure in non\u2010muscle\u2010invasive bladder cancer: an update","volume":"3","author":"Zlotta AR","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.7326\/M22-0276","article-title":"QUAPAS: An adaptation of the QUADAS\u20102 tool to assess prognostic accuracy studies","volume":"175","author":"Lee J","year":"2022","journal-title":"Ann Intern Med"},{"issue":"1","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff RF","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.1996.14.10.2646","article-title":"Overexpression of p53 protein in a high\u2010risk population of patients with superficial bladder cancer before and after bacillus Calmette\u2010Gu\u00e9rin therapy: correlation to clinical outcome","volume":"14","author":"Lacombe L","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1442-2042.1997.tb00307.x","article-title":"Prognostic markers of intravesical bacillus Calmette\u2010Gu\u00e9rin therapy for multiple, high\u2010grade, stage T1 bladder cancers","volume":"4","author":"Lee E","year":"1997","journal-title":"Int J Urol"},{"issue":"4","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2003.11.018","article-title":"Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette\u2010Gu\u00e9rin (BCG)","volume":"45","author":"Saint F","year":"2004","journal-title":"Eur Urol"},{"issue":"2","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000343431","article-title":"Prognostic factors including Ki\u201067 and p53 in bacillus Calmette\u2010Gu\u00e9rin\u2010treated non\u2010muscle\u2010invasive bladder cancer: a prospective study","volume":"90","author":"Oderda M","year":"2013","journal-title":"Urol Int"},{"issue":"4","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/00365590601183055","article-title":"Prognostic value of p53, Ki\u201067, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression","volume":"41","author":"Queipo\u2010Zaragoza JA","year":"2007","journal-title":"Scand J Urol Nephrol"},{"issue":"2","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-5347(01)64485-9","article-title":"Prognostic value of Ki\u201067 for recurrence and progression of superficial bladder cancer","volume":"158","author":"Asakura T","year":"1997","journal-title":"J Urol"},{"issue":"1","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2012.05.033","article-title":"Combination of CK20 and Ki\u201067 immunostaining analysis predicts recurrence, progression, and cancer\u2010specific survival in pT1 urothelial bladder cancer","volume":"65","author":"Bertz S","year":"2014","journal-title":"Eur Urol"},{"issue":"26","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor\u2010infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette\u2010Gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler R","year":"2016","journal-title":"Oncotarget"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim CJ","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","article-title":"Clinical role of programmed cell Death\u20101 expression in patients with non\u2010muscle\u2010invasive bladder cancer recurring after initial bacillus Calmette\u2010Gu\u00e9rin therapy","volume":"25","author":"Fukumoto K","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bju.15582","article-title":"Predictive value of immunological markers after bacille Calmette\u2010Gu\u00e9rin induction in bladder cancer","volume":"130","author":"Elsawy AA","year":"2022","journal-title":"BJU Int"},{"issue":"3","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/etm.2012.634","article-title":"Prediction of response to bacillus Calmette\u2010Gu\u00e9rin treatment in non\u2010muscle invasive bladder cancer patients through interleukin\u20106 and interleukin\u201010 ratio","volume":"4","author":"Cai T","year":"2012","journal-title":"Exp Ther Med"},{"issue":"2","key":"e_1_2_10_28_1","article-title":"High baseline levels of interleukin\u20108 in leukocytes and urine predict tumor recurrence in non\u2010muscle invasive bladder cancer patients receiving bacillus Calmette\u2010Guerin therapy: a long\u2010term survival analysis","volume":"6","author":"Qu K","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"1","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/CBM-210221","article-title":"Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: a pilot study","volume":"33","author":"Murakami K","year":"2022","journal-title":"Cancer Biomark"},{"issue":"2","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette\u2010Gu\u00e9rin","volume":"69","author":"Kamat AM","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/bju.16697","article-title":"Bladder EpiCheck clinical utility to predict BCG response in non\u2010muscle\u2010invasive bladder cancer","volume":"136","author":"Rold\u00e1n FL","year":"2025","journal-title":"BJU Int"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.euros.2021.02.005","article-title":"The use of urine mycobacterium tuberculosis complex polymerase chain reaction as a predictive factor for recurrence and progression after intravesical bacillus Calmette\u2010Gu\u00e9rin therapy in patients with non\u2010muscle\u2010invasive bladder cancer","volume":"27","author":"Muto S","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"8","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081839","article-title":"Discovery of molecular DNA methylation\u2010based biomarkers through genome\u2010wide analysis of response patterns to BCG for bladder cancer","volume":"9","author":"Ilijazi D","year":"2020","journal-title":"Cells"},{"issue":"5","key":"e_1_2_10_34_1","first-page":"2255","article-title":"Re: history of bacillus Calmette\u2010Guerin and bladder cancer: an immunotherapy success story","volume":"180","author":"Koyama A","year":"2008","journal-title":"J Urol"},{"issue":"3","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.urolonc.2008.08.003","article-title":"Retinoblastoma protein expression predicts response to bacillus Calmette\u2010Gu\u00e9rin immunotherapy in patients with T1G3 bladder cancer","volume":"28","author":"Cormio L","year":"2010","journal-title":"Urol Oncol"},{"issue":"10","key":"e_1_2_10_36_1","first-page":"4201","article-title":"Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer","volume":"29","author":"Cormio L","year":"2009","journal-title":"Anticancer Res"},{"issue":"8","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0344-0338(97)80013-1","article-title":"Prognostic significance of Ki\u201067 expression in transitional cell bladder carcinoma after radical cystectomy","volume":"193","author":"Suwa Y","year":"1997","journal-title":"Pathol Res Pract"},{"issue":"5","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette\u2010Gu\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a southern Europe population","volume":"116","author":"Lima L","year":"2015","journal-title":"BJU Int"},{"issue":"1","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3233\/DMA-2011-0816","article-title":"Role of p53 gene polymorphism and bladder cancer predisposition in northern India","volume":"8","author":"Srivastava P","year":"2010","journal-title":"Cancer Biomark"},{"issue":"8","key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin\u20102 may predict clinical outcome of intravesical bacillus Calmette\u2010Gu\u00e9rin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe E","year":"2003","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0974-7796.84954","article-title":"Long\u2010term prognostic value of the combination of EORTC risk group calculator and molecular markers in non\u2010muscle\u2010invasive bladder cancer patients treated with intravesical Bacille Calmette\u2010Gu\u00e9rin","volume":"3","author":"Alkhateeb SS","year":"2011","journal-title":"Urol Ann"},{"issue":"13","key":"e_1_2_10_42_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang S","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","article-title":"Systemic immune response after intravesical instillation of bacille Calmette\u2010Gu\u00e9rin (BCG) for superficial bladder cancer","volume":"115","author":"Taniguchi K","year":"1999","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"e_1_2_10_44_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092514","article-title":"Liquid biopsy biomarkers in bladder cancer: a current need for patient diagnosis and monitoring","volume":"19","author":"Lodewijk I","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"12","key":"e_1_2_10_45_1","article-title":"Liquid biopsy: An evolving paradigm for non\u2010invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit KK","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"e_1_2_10_46_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152343","article-title":"Liquid biopsy: An innovative tool in oncology. Where do we stand?","volume":"52","author":"Martella S","year":"2025","journal-title":"Semin Oncol"},{"issue":"6","key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.euf.2024.05.024","article-title":"Diagnostic test accuracy of urinary DNA methylation\u2010based biomarkers for the detection of primary and recurrent bladder cancer: a systematic review and meta\u2010analysis","volume":"10","author":"Silva\u2010Ferreira M","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"3","key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer \u2013 a current perspective","volume":"11","author":"Redelman\u2010Sidi G","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"1","key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non\u2010muscle\u2010invasive bladder cancer treated with bacillus Calmette\u2010Gu\u00e9rin","volume":"5","author":"Lobo N","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC\u2010GU cancers group randomized study of maintenance bacillus Calmette\u2010Gu\u00e9rin in intermediate\u2010 and high\u2010risk Ta, T1 papillary carcinoma of the urinary bladder: one\u2010third dose versus full dose and 1 year versus 3\u2009years of maintenance","volume":"63","author":"Oddens J","year":"2013","journal-title":"Eur Urol"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149590","article-title":"Uncovering citron kinase as a key biomarker for predicting outcomes and therapy efficacy in non\u2010muscle\u2010invasive bladder cancer","volume":"963","author":"Deng P","year":"2025","journal-title":"Gene"},{"issue":"5","key":"e_1_2_10_52_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104120","article-title":"Roles for androgen receptor, ADAR2, and PD\u2010L1 in primary urothelial carcinoma in situ of the bladder treated with bacillus Calmette\u2010Gu\u00e9rin therapy","volume":"105","author":"Ricciardi G","year":"2025","journal-title":"Lab Invest"},{"issue":"4","key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/pin.70002","article-title":"Evaluation of NANOG\/HDAC1 expression in predicting outcomes of BCG therapy in non\u2010muscle invasive bladder cancer","volume":"75","author":"Yamashita T","year":"2025","journal-title":"Pathol Int"},{"key":"e_1_2_10_54_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155997","article-title":"Infiltrating natural killer cells influence the efficacy of BCG immunotherapy in non\u2010muscle\u2010invasive bladder cancer","volume":"270","author":"Lima MZT","year":"2025","journal-title":"Pathol Res Pract"},{"issue":"1","key":"e_1_2_10_55_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41698-024-00725-4","article-title":"The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCG","volume":"8","author":"Xia QD","year":"2024","journal-title":"npj Precis Oncol"},{"key":"e_1_2_10_56_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1442555","article-title":"The clinical significance and anti\u2010tumor role of PRKG1 in bladder cancer","volume":"15","author":"Jin L","year":"2024","journal-title":"Front Immunol"},{"key":"e_1_2_10_57_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102003","article-title":"Immune\u2010checkpoint gene expression and BCG response in non\u2010muscle invasive bladder cancer","volume":"46","author":"Zucca LER","year":"2024","journal-title":"Transl Oncol"},{"key":"e_1_2_10_58_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1301510","article-title":"HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk\u2010stratified cohort of bladder cancer","volume":"14","author":"Nam W","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"e_1_2_10_59_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","article-title":"Prognostic significance of HER2 expression in patients with bacillus Calmette\u2010Gu\u00e9rin\u2010exposed non\u2010muscle\u2010invasive bladder cancer","volume":"7","author":"Tan X","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"e_1_2_10_60_1","article-title":"Combined assessment of peritumoral Th1\/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high\u2010risk NMIBC","volume":"8","author":"Mart\u00ednez R","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"12","key":"e_1_2_10_61_1","doi-asserted-by":"crossref","first-page":"531.e9","DOI":"10.1016\/j.urolonc.2018.09.007","article-title":"Heat shock proteins 60 and 70 are associated with long\u2010term outcome of T1\u2010stage high\u2010grade urothelial tumors of the bladder treated with intravesical bacillus Calmette\u2010Gu\u00e9rin immunotherapy","volume":"36","author":"Mano R","year":"2018","journal-title":"Urol Oncol"},{"issue":"9","key":"e_1_2_10_62_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184841","article-title":"Interleukin\u201017\u2010positive mast cells influence outcomes from BCG for patients with CIS: data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer","volume":"12","author":"Dowell AC","year":"2017","journal-title":"PLoS One"},{"issue":"15","key":"e_1_2_10_63_1","doi-asserted-by":"crossref","first-page":"25433","DOI":"10.18632\/oncotarget.15989","article-title":"Human epidermal growth factor receptor 2 expression is more important than bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer","volume":"8","author":"Cormio L","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"e_1_2_10_64_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102186","article-title":"Regulatory T\u00a0cells and tumor\u2010associated macrophages in the tumor microenvironment in non\u2010muscle invasive bladder cancer treated with intravesical Bacille Calmette\u2010Gu\u00e9rin: a long\u2010term follow\u2010up study of a Japanese cohort","volume":"18","author":"Miyake M","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"4","key":"e_1_2_10_65_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.juro.2014.10.098","article-title":"\u0394Np63 expression is a protective factor of progression in clinical high grade T1 bladder cancer","volume":"193","author":"Gaya JM","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"e_1_2_10_66_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urolonc.2013.10.012","article-title":"The predominance of M2\u2010polarized macrophages in the stroma of low\u2010hypoxic bladder tumors is associated with BCG immunotherapy failure","volume":"32","author":"Lima L","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"e_1_2_10_67_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/01913123.2012.728688","article-title":"Prognostic value of tumor\u2010associated macrophages count in human non\u2010muscle\u2010invasive bladder cancer treated by BCG immunotherapy","volume":"37","author":"Ajili F","year":"2013","journal-title":"Ultrastruct Pathol"},{"issue":"1","key":"e_1_2_10_68_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/01913123.2011.620221","article-title":"Prognostic value of Bcl\u20102 and Bax tumor cell expression in patients with non muscle\u2010invasive bladder cancer receiving bacillus Calmette\u2010Guerin immunotherapy","volume":"36","author":"Ajili F","year":"2012","journal-title":"Ultrastruct Pathol"},{"issue":"5","key":"e_1_2_10_69_1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/01913123.2012.672847","article-title":"Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34","volume":"36","author":"Ajili F","year":"2012","journal-title":"Ultrastruct Pathol"},{"key":"e_1_2_10_70_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/1471-2407-12-459","article-title":"Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression\u2010free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer","volume":"12","author":"Otto W","year":"2012","journal-title":"BMC Cancer"},{"issue":"5","key":"e_1_2_10_71_1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.juro.2009.12.105","article-title":"Loss of heterozygosis on IFN\u2010\u03b1 locus is a prognostic indicator of bacillus Calmette\u2010Guerin response for nonmuscle invasive bladder cancer","volume":"183","author":"Cai T","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"e_1_2_10_72_1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette\u2010Gu\u00e9rin","volume":"56","author":"Palou J","year":"2009","journal-title":"Eur Urol"},{"issue":"6","key":"e_1_2_10_73_1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette\u2010Gu\u00e9rin immunotherapy","volume":"55","author":"Ayari C","year":"2009","journal-title":"Eur Urol"},{"issue":"7","key":"e_1_2_10_74_1","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.21037\/tau-21-158","article-title":"Genomic analysis of response to bacillus Calmette\u2010Gu\u00e9rin (BCG) treatment in high\u2010grade stage 1 bladder cancer patients","volume":"10","author":"Sanders JA","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"2","key":"e_1_2_10_75_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/BLC-200289","article-title":"Genomic biomarkers and underlying mechanism of benefit from BCG immunotherapy in non\u2010muscle invasive bladder cancer","volume":"6","author":"Bastos DA","year":"2020","journal-title":"Bladder Cancer"},{"issue":"3","key":"e_1_2_10_76_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030947","article-title":"TERT promoter mutation as a potential predictive biomarker in BCG\u2010treated bladder cancer patients","volume":"21","author":"Batista R","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"e_1_2_10_77_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette\u2010Gu\u00e9rin response in patients with T1G3 high\u2010risk bladder tumours","volume":"60","author":"Agundez M","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"e_1_2_10_78_1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.juro.2010.05.085","article-title":"Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer","volume":"184","author":"Alvarez\u2010M\u00fagica M","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"e_1_2_10_79_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00428-010-0969-6","article-title":"Cyclin D3 gene amplification in bladder carcinoma in situ","volume":"457","author":"Lopez\u2010Beltran A","year":"2010","journal-title":"Virchows Arch"},{"issue":"5","key":"e_1_2_10_80_1","doi-asserted-by":"crossref","first-page":"197.e1","DOI":"10.1016\/j.urolonc.2021.12.009","article-title":"Expression of RPL9 predicts the recurrence of non\u2010muscle invasive bladder cancer with BCG therapy","volume":"40","author":"Piao XM","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"e_1_2_10_81_1","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.clgc.2021.12.001","article-title":"Identification of different miRNAs and their relevant miRNA targeted genes involved in sister chromatid cohesion and segregation (SCCS)\/chromatin remodeling pathway on T1G3 urothelial carcinoma (UC) response to BCG immunotherapy","volume":"20","author":"Awadalla A","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"e_1_2_10_82_1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","article-title":"Gene signatures for the prediction of response to bacillus Calmette\u2010Guerin immunotherapy in primary pT1 bladder cancers","volume":"16","author":"Kim YJ","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"e_1_2_10_83_1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/bjc.2013.571","article-title":"Response of high\u2010risk of recurrence\/progression bladder tumours expressing sialyl\u2010Tn and sialyl\u20106\u2010T to BCG immunotherapy","volume":"109","author":"Lima L","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"e_1_2_10_84_1","doi-asserted-by":"crossref","first-page":"44.e1","DOI":"10.1016\/j.urolonc.2013.05.009","article-title":"FASL polymorphism is associated with response to bacillus Calmette\u2010Gu\u00e9rin immunotherapy in bladder cancer","volume":"32","author":"Lima L","year":"2014","journal-title":"Urol Oncol"},{"issue":"3","key":"e_1_2_10_85_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/iju.15106","article-title":"C\u2010reactive protein as a prognostic predictor for non\u2010muscle invasive bladder cancer after intravesical bacillus Calmette\u2010Gu\u00e9rin therapy: a Japan urological oncology group study analysis","volume":"30","author":"Nishikawa R","year":"2023","journal-title":"Int J Urol"},{"issue":"1","key":"e_1_2_10_86_1","article-title":"Serum CCL27 predicts the response to bacillus Calmette\u2010Guerin immunotherapy in non\u2010muscle\u2010invasive bladder cancer","volume":"9","author":"Zhong W","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"11","key":"e_1_2_10_87_1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.urolonc.2016.05.013","article-title":"Prognostic significance of markers of systemic inflammatory response in patients with non\u2010muscle\u2010invasive bladder cancer","volume":"34","author":"Mbeutcha A","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"e_1_2_10_88_1","article-title":"Differential role of NKG2A\/HLA\u2010E interaction in the outcomes of bladder cancer patients treated with M. Bovis BCG or other therapies","volume":"13","author":"Ruiz\u2010Lorente I","year":"2025","journal-title":"Biomedicine"},{"issue":"3","key":"e_1_2_10_89_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-021-03032-0","article-title":"Effect of HLA genotype on intravesical recurrence after bacillus Calmette\u2010Gu\u00e9rin therapy for non\u2010muscle\u2010invasive bladder cancer","volume":"71","author":"Kobayashi M","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"e_1_2_10_90_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.redox.2015.08.008","article-title":"Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes","volume":"6","author":"Ryk C","year":"2015","journal-title":"Redox Biol"},{"issue":"5","key":"e_1_2_10_91_1","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1007\/s11033-011-1366-1","article-title":"Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in north Indian cohort","volume":"39","author":"Jaiswal PK","year":"2012","journal-title":"Mol Biol Rep"},{"issue":"3","key":"e_1_2_10_92_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette\u2010Gu\u00e9rin therapy for bladder cancer","volume":"59","author":"Chiong E","year":"2011","journal-title":"Eur Urol"},{"issue":"1","key":"e_1_2_10_93_1","doi-asserted-by":"crossref","DOI":"10.1177\/23523735251325100","article-title":"Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after bacillus Calmette\u2010Gu\u00e9rin therapy in patients with non\u2010muscle invasive bladder cancer","volume":"11","author":"Miyake M","year":"2025","journal-title":"Bladder Cancer"},{"issue":"5","key":"e_1_2_10_94_1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/1097-0142(19870901)60:5<1009::AID-CNCR2820600515>3.0.CO;2-B","article-title":"The practical use of tumor marker determination in bladder washing specimens. Assessing the urothelium of patients with superficial bladder cancer","volume":"60","author":"Orihuela E","year":"1987","journal-title":"Cancer"},{"issue":"2","key":"e_1_2_10_95_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.32604\/or.2023.028163","article-title":"A Th2\u2010score in the tumor microenvironment as a predictive biomarker of response to bacillus Calmette Gu\u00e9rin in patients with non\u2010muscle invasive bladder carcinoma: a retrospective study","volume":"31","author":"Villoldo GM","year":"2023","journal-title":"Oncol Res"},{"issue":"5","key":"e_1_2_10_96_1","doi-asserted-by":"crossref","first-page":"242.e9","DOI":"10.1016\/j.urolonc.2018.02.002","article-title":"The role of neural precursor cell\u2010expressed developmentally down\u2010regulated protein 9 in predicting bacillus Calmette\u2010Guerin response in nonmuscle invasive bladder cancer","volume":"36","author":"El\u2010Babouly IM","year":"2018","journal-title":"Urol Oncol"},{"issue":"1","key":"e_1_2_10_97_1","doi-asserted-by":"crossref","first-page":"45.e23","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette\u2010Gu\u00e9rin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez\u2010Nateras R","year":"2014","journal-title":"Urol Oncol"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1878-0261.70329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:11:38Z","timestamp":1788765098000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1878-0261.70329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":96,"alternative-id":["10.1002\/1878-0261.70329"],"URL":"https:\/\/doi.org\/10.1002\/1878-0261.70329","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"2026-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1878-0261.70329"}}